达标治疗策略对比症状驱动管理痛风:GO TEST Overture随机对照试验
在荷兰8家二级风湿病中心开展的开放标签、实用性、优效性随机对照试验,纳入308例未使用降尿酸治疗的痛风伴高尿酸血症患者,比较达标治疗(血尿酸目标<0·36 mmol/L)与症状驱动管理。达标治疗组随访18-24个月缓解率显著高于症状驱动组(39·4% vs 24·0%,绝对差15·4个百分点,95%CI 6·4-24·4,p=0·024),不良事件未见显著增加。
要点
- 达标治疗组18-24个月缓解率39·4%,显著优于症状驱动组的24·0%。
- 达标治疗组不良事件发生率42%,症状驱动组53%,差异无统计学意义。
- 结果支持在痛风常规管理中系统使用血尿酸引导的降尿酸治疗滴定。
核心结论
- 达标治疗策略较症状驱动管理改善痛风长期疾病控制,且未增加不良事件。
研究设计与样本
- 多中心、开放标签、实用性、优效性随机对照试验,在荷兰8家二级风湿病中心开展,纳入308例≥18岁痛风伴高尿酸血症且未使用降尿酸治疗的患者,1:1随机分组。
主要发现
- 随访18-24个月缓解率达标治疗组39·4%(57/145)高于症状驱动组24·0%(39/163),绝对差15·4个百分点(95%CI 6·4-24·4;p=0·024)。
- 不良事件达标治疗组61例(42%),症状驱动组86例(53%),绝对差-10·7个百分点(95%CI -21·8至0·4;p=0·060)。
- 未报告严重药物相关不良事件及治疗相关死亡。
关键数值与推荐
- 达标治疗组以血清尿酸<0·36 mmol/L为目标,结构化滴定口服降尿酸治疗(一线别嘌醇,二线非布司他或苯溴马隆)。
- 缓解定义为随访18-24个月无痛风发作、24个月无皮下痛风石、患者报告疼痛评分<2且患者整体疾病活动度评分>8。
临床怎么用
- 对痛风伴高尿酸血症且未使用降尿酸治疗的患者,可采用血尿酸引导的达标治疗策略进行降尿酸治疗滴定。
局限性
- 开放标签设计,参与者和研究者未设盲。
- 研究在荷兰二级风湿病中心开展,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A treat-to-target approach is recommended for gout management, which involves titrating urate-lowering therapy to reach a serum urate target of less than 0·36 mmol/L, but evidence from pragmatic, head-to-head trials comparing a treat-to-target strategy with a symptom-driven approach is scarce. We aimed to address this gap by comparing these two approaches in patients with gout. METHODS: We did a multicentre, open-label, pragmatic, superiority, randomised controlled trial at eight secondary care rheumatology centres in the Netherlands. Participants aged 18 years or older with gout and hyperuricaemia (typically defined as a serum urate concentration of >0·36 mmol/L), and not currently using urate-lowering therapy were randomly assigned (1:1) using a computer-generated allocation sequence to receive either a treat-to-target strategy to reach a target serum urate concentration of less than 0·36 mmol/L with structured serum urate-guided titration of oral urate-lowering therapy (including first-line allopurinol and second-line oral febuxostat or oral benzbromarone) or symptom-driven management, in which the physicians and patients decided whether to initiate urate-lowering therapy based on symptoms, and the type and dose were determined at the physician's discretion without a specific serum urate target. Because of the pragmatic design, participants and investigators were not masked to treatment allocation. The primary outcome was remission during months 18-24 of follow-up, defined as absence of gout flares during months 18-24, no subcutaneous tophi at month 24, a patient-reported pain score of less than 2, and a patient global assessment of disease activity score of more than 8. Analyses were done according to the intention-to-treat principle using multiple imputation for missing data, and all randomly assigned participants were included in the primary efficacy and safety analyses. People with lived experience of gout contributed to the study design and selection of outcome measures. The trial was registered with EudraCT, 2020-005721-82, and is closed to recruitment. FINDINGS: Between March 4, 2021, and Nov 4, 2022, 308 participants were randomly assigned, of whom 268 (87%) were male and 40 (13%) were female; the mean age was 65·93 years (SD 15·29). Participants were allocated to the treat-to-target group (145 participants) or the symptom-driven management group (163 participants). Remission during months 18-24 occurred more often in the treat-to-target group than in the symptom-driven management group (39·4% [57 of 145 participants] vs 24·0% [39 of 163]; absolute difference 15·4 percentage points [95% CI 6·4-24·4]; p=0·024). Adverse events occurred in 61 (42%) participants in the treat-to-target group and 86 (53%) in the symptom-driven management group (absolute difference -10·7 percentage points [95% CI -21·8 to 0·4; p=0·060). No serious drug-related adverse events and no treatment-related deaths were reported. INTERPRETATION: A treat-to-target strategy was associated with improved long-term disease control compared with symptom-driven care, without evidence of increased adverse events. These findings provide support for the use of systematic serum urate-guided urate-lowering therapy titration in the routine management of gout. FUNDING: ZonMW and Reuma Nederland.
引用
- Moses A, Oude Voshaar MAH, van Geel EH, et al. A treat-to-target strategy versus symptom-driven management of gout in the Netherlands (GO TEST Overture): a multicentre, open-label, pragmatic, superiority, randomised controlled trial. Lancet Rheumatol. 2026. PMID: 41865749. doi:10.1016/S2665-9913(26)00034-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。